These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21502814)

  • 1. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.
    Jiang Z; Jones R; Liu JC; Deng T; Robinson T; Chung PE; Wang S; Herschkowitz JI; Egan SE; Perou CM; Zacksenhaus E
    Cell Cycle; 2011 May; 10(10):1563-70. PubMed ID: 21502814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.
    Jiang Z; Deng T; Jones R; Li H; Herschkowitz JI; Liu JC; Weigman VJ; Tsao MS; Lane TF; Perou CM; Zacksenhaus E
    J Clin Invest; 2010 Sep; 120(9):3296-309. PubMed ID: 20679727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
    Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
    J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
    Robinson TJ; Liu JC; Vizeacoumar F; Sun T; Maclean N; Egan SE; Schimmer AD; Datti A; Zacksenhaus E
    PLoS One; 2013; 8(11):e78641. PubMed ID: 24265703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.
    Kumar P; Mukherjee M; Johnson JP; Patel M; Huey B; Albertson DG; Simin K
    PLoS Genet; 2012; 8(11):e1003027. PubMed ID: 23173005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition.
    Markiewicz A; Topa J; Popęda M; Szade J; Skokowski J; Wełnicka-Jaśkiewicz M; Żaczek A
    Acta Biochim Pol; 2021 Aug; 68(3):385-392. PubMed ID: 34432400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
    Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
    Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
    Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
    Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
    Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
    Hacking SM; Yakirevich E; Wang Y
    J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.
    Chung WC; Zhang S; Challagundla L; Zhou Y; Xu K
    Neoplasia; 2017 Nov; 19(11):885-895. PubMed ID: 28938159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
    Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
    Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
    Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer--current status and future directions.
    Gluz O; Liedtke C; Gottschalk N; Pusztai L; Nitz U; Harbeck N
    Ann Oncol; 2009 Dec; 20(12):1913-27. PubMed ID: 19901010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.